Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Guidance

Subcategories:EthicsLegal UpdatesLegislation & AdvocacyResearch Rheum

Figure 2: High-resolution computed tomography showed evidence of interstitial lung disease.

High-resolution computed tomography shows evidence of ILD.

The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!

 

3 New Study Summaries from AC&R: Obesity in RA, CPDD Risk Factors & SLE Disparities

Joshua F. Baker, MD, MSCE; Joel Kremer, MD; Jean Lieuw, MD, MS; Alfredo Aguirre, MD; & Jinoos Yazdany, MD, MPH  |  August 14, 2022

1) Obesity & Treatment Response in RA Obesity & response to advanced therapies in rheumatoid arthritis Why was this study done? There have been questions regarding whether certain therapies for rheumatoid arthritis (RA) are less effective in patients with obesity, particularly for tumor necrosis factor (TNF) inhibitors, because adipose tissue is known to generate TNF,…

Florida Law Puts Drug Pricing by Pharmacy Benefit Managers Under a Microscope Once Again

Catherine Kolonko  |  August 8, 2022

As of July 1, a Florida bill increases oversight of pharmacy benefit managers and offers some protection for pharmacies. However, the legislation has limited effects on patients and providers, highlighting the need for additional reform.

Ongoing Advocacy Efforts Seek Use of Complex Administration Codes for Biologics

From the College  |  August 8, 2022

Ongoing ACR advocacy efforts are working to keep biologic drugs accessible to rheumatology patients, defending the ability of rheumatology practices to use the complex chemotherapy codes for administration of biologic therapies.

The ACR’s RISE Registry & Rheumatology Research Foundation Launch Award to Support Early Career Professionals

Allison Plitman, MPA  |  August 5, 2022

A new award from the ACR’s RISE Registry and the Rheumatology Research Foundation supports early career rheumatology researchers and clinicians who leverage the registry’s real-world data in research projects.

COVID-19 Vaccinations in Immune-Compromised Patients

Arthritis & Rheumatology  |  July 27, 2022

A prospective observational study by Syversen et al. found that patients with immune-mediated inflammatory diseases (IMID) had an attenuated serologic response to the standard two-dose vaccine regimen but a third dose was safe and effective.

How to Connect with Your Members of Congress During the August Recess

From the College  |  July 22, 2022

Many members of Congress return to their home states and districts in August, making it a great time to engage them in local conversations about healthcare policies and how they affect rheumatology practices and patients.

Ethics Forum: Billing, Burnout and Protected Non-Clinical Time

Beenish Zulfiqar, MD  |  July 14, 2022

It’s 11 a.m. on a Wednesday. You see a new patient in your fellow’s clinic with impressive physical findings, including a prominent skin rash and deforming arthritis. The patient has been to many doctors and is frustrated that her condition remains undiagnosed and untreated. You thoroughly examine the patient, present her case to your attending…

The ACR Responds to Impact of the Dobbs v. Jackson Decision on Rheumatology Patients and Providers

Joseph Cantrell, JD, & Kenneth G. Saag, MD, MSc  |  July 13, 2022

The ACR and a new Access to Reproductive Health Care Task Force are working to ensure patients with rheumatic disease—particularly women—have access to the medications and treatments they need, including methotrexate, and that rheumatology providers are able to maintain trusting relationships with and advise their patients on all matters relevant to the management of their rheumatic diseases.

CMS Releases CY23 Medicare Physician Fee Schedule & Quality Payment Program Updates

From the College  |  July 10, 2022

If enacted as is, the proposed CY 2023 Medicare Physician Fee Schedule and Quality Payment Program would make significant cuts to reimbursement for evaluation and management services, creating financial instability for providers. On a positive note, it would extend some telehealth flexibilities 151 days beyond the official end of the public health emergency.

Cigna Delays Modifier 25 Policy Change for Evaluation & Management Services

From the College  |  July 7, 2022

Cigna will not move forward with changes to their reimbursement policy for evaluation and management (E/M) codes submitted with modifier 25 as originally scheduled.

  • « Previous Page
  • 1
  • …
  • 32
  • 33
  • 34
  • 35
  • 36
  • …
  • 244
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences